Three Signs the Bottom is In | WAYT?
Speakers
Summary
- Market Bottom Debate: Speakers debate if the recent low was the bottom. Michael Batnick assigns a 40% chance, citing potential for escalation (e.g., a European oil tanker attack) as a key risk. Josh Brown is more confident (59-69%), arguing the market is looking past current Middle East tensions toward earnings.
- Dividend Literacy: Discusses a survey revealing low investor understanding of dividend mechanics, with only ~25% of individuals knowing the share price adjusts downward on the ex-date, contrasting it with bank account interest.
- ETF Competition: Analysis of BlackRock's planned, lower-fee Nasdaq 100 ETF (IQQ) as a potential threat to Invesco's dominant QQQ. The moat is seen as defensible for traders/derivatives due to QQQ's liquidity, but institutional "sticky" assets could migrate.
- Market Rotation & Leadership: Highlights a massive dispersion in returns: the "MAG 7" have been significant detractors YTD, while physical asset/industrial stocks (e.g., XOM, CVX, CAT, MU) have been the top contributors, supporting a "spenders vs. recipients" AI trade thesis.
- Value vs. Growth: Notes value stocks had their strongest quarterly outperformance vs. growth since 2001. Batnick believes it has "legs" and could continue into Q2, while acknowledging investor skepticism due to past failed value rallies.
- JP Morgan Fortress Balance Sheet: Josh Brown extensively praises JPM's risk management, consistent high Return on Tangible Common Equity (~20%), and strategic acquisitions of failed competitors, framing it as a long-term "fortress" holding.
- OpenAI Valuation & Strategy: Discusses OpenAI's massive $122B funding round at an $852B valuation and its acquisition of a tech podcast (TBPN). Views are mixed: one sees it as a strategic PR move; the other cites it as an example of seemingly nonsensical decisions by a highly valued entity.
- Biotech Technical Strength: Josh Brown presents charts for biotech ETFs (XBI, IBB), noting they are "acting great technically" and consolidating, with XBI/IBB ratio suggesting more room for the equal-weighted fund to run.
- Netflix Setup: Technical analysis of NFLX suggests a bullish setup with a clear stop-loss level ($90), a price target ($120), and positive fundamentals post-price hike.
Trade Ideas
Speaker highlights JP Morgan's "fortress balance sheet," consistent ~20% Return on Tangible Common Equity, strategic acquisitions of failed banks (e.g., First Republic), and its status as a beneficiary of industry consolidation. These factors demonstrate superior risk management, operational efficiency, and an ability to grow through crisis, creating a durable competitive advantage. LONG for long-term ownership, viewed as a core holding that doesn't need to be sold due to temporary analyst downgrades or short-term price moves. A systemic banking crisis severe enough to breach its risk management.
Speaker presents charts showing the Biotech ETFs (XBI - equal-weighted, IBB - cap-weighted) are "acting great technically" and consolidating, with the XBI/IBB ratio suggesting further relative upside for XBI. The improving technical posture, after a prolonged period of weakness, indicates building momentum and a potential breakout. LONG on biotech ETFs, with a preference for the equal-weighted XBI based on the ratio chart. A broader market sell-off negating the sector's technical strength.
Technical analysis shows NFLX price action "acting very well," having held a prior gap, with the next resistance at ~$120. A stop-loss is identified at $90. Fundamentals are cited as strong post-price hike. The defined technical levels ($90 stop, $120 target) create a favorable risk/reward setup (risking ~$9 to make ~$20). LONG based on the technical setup and positive fundamental backdrop. Price breaking down below the $90 support level.
Up Next
This The Compound News video, published April 07, 2026, features Josh Brown discussing JPM, XBI, IBB, NFLX. 3 trade ideas extracted by AI with direction and confidence scoring.
Speakers: Josh Brown · Tickers: JPM, XBI, IBB, NFLX